Abstract:
Fused thiazolidine moiety heterocycles are an integral part of new drug discovery in anti-inflammatory research. We are reporting novel N3 substituted 5,7-dimethyl-6-phenylazo-3Н-thiazolo[4,5-b]pyridin-2-ones synthesis as the integral part of scaffold-based biologically active compounds design and their discovery as potential drug candidates using traditional organic synthesis protocols and pharmacological screening methodologies. The synthetic protocol developed for thiazolo[4,5-b]pyridines construction and the wide range of their biological responses highlight the therapeutic interest of designing this scaffold-based compounds. A series of novel thiazolo[4,5-b]pyridines derivatives testing over the carageenin induced rat paw edema revealed strong anti-inflammatory action of some compounds which exceeded that one of Diclofenac.